Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhengqing Fengtongning sustained-release tablets for prevention of gout flares during urate-lowering therapy
ChiCTR2100045114Phase 4Recruiting
- Sponsor
- Shenzhen Traditional Chinese Medicine Hospital
- Start
- Mar 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of zhengqing fengtongning and colchicine in gout (2 arms), sponsored by Shenzhen Traditional Chinese Medicine Hospital. Primary endpoint: Rate of gout flares. Started Mar 2021; status: recruiting.
02
Drugs
zhengqing fengtongningcolchicine
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR2100045114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045114.